Compare Davita Inc (DVA) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs New York Times Co — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while New York Times Co trades at $64.2 (market cap $10.45B). The key difference: Davita Inc and New York Times Co are close in size by market cap, and New York Times Co pays a 1.42% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NYT | |
|---|---|---|
Market Cap | $11.72B | $10.45B |
Sector | Health | Media |
52-Week High | $240.96 | $85.86 |
52-Week Low | $103.87 | $54.66 |
Enterprise Value | $24.44B | $9.85B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
The New York Times (NYT) stock trades at $63.54, down 1.9% recently, with a bearish technical signal from moving averages but neutral oscillators. Fundamentally, the company shows strong profitability with a 13.19% net income margin and consistent earnings beats, including Q2 2026 EPS of $0.69 versus $0.663 expected. Revenue growth is steady, reaching $2.82B in 2025, though digital subscriber additions have moderated, contributing to near-term stock weakness.
Outlook remains mixed; analyst consensus targets $77.50 with 29% buy ratings, but slower subscriber growth and high valuation (P/E 26.48) pose risks. Opportunities include digital expansion and pricing power, while risks involve competition and economic sensitivity. The stock's current level near support at $63 may attract value-oriented investors if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
